Search research articles
Contact Us
Filters
Showing results (111-120 of 122) with videos related to
Page
of 13
Sort By:
Clinical Lung Cancer
|
March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)
Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
Cancer Chemotherapy and Pharmacology
|
September 25, 2019
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Leonard J Appleman, Jan H Beumer, Yixing Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2014
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer
Neil D Gross, Julie E Bauman, William E Gooding, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2021
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort
Paolo Bossi, Annalisa Trama, Alice Bernasconi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial
Ralph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2009
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms
Stephen Y Lai, Priya Koppikar, Sufi M Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2022
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.
Cancer Treatment Reviews
|
June 28, 2026
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck
Carlo Resteghini, Athanassios Argiris, Pierre Blanchard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2021
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Adam J Luginbuhl, Jennifer M Johnson, Larry A Harshyne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2025
Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
Pablo Llerena, Hani Samarah, Kathryn Nunes, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 122) with videos related to
Sort By:
Page
of 13
Clinical Lung Cancer
|
March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)
Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
Cancer Chemotherapy and Pharmacology
|
September 25, 2019
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
Leonard J Appleman, Jan H Beumer, Yixing Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2014
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer
Neil D Gross, Julie E Bauman, William E Gooding, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2021
Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort
Paolo Bossi, Annalisa Trama, Alice Bernasconi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 12, 2025
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial
Ralph G Zinner, Eric V Mastrolonardo, Jennifer M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2009
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms
Stephen Y Lai, Priya Koppikar, Sufi M Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2022
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.
Cancer Treatment Reviews
|
June 28, 2026
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck
Carlo Resteghini, Athanassios Argiris, Pierre Blanchard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2021
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
Adam J Luginbuhl, Jennifer M Johnson, Larry A Harshyne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 11, 2025
Extracellular Matrix-MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
Pablo Llerena, Hani Samarah, Kathryn Nunes, et al.
Page
of 13